{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:45:48Z","timestamp":1791229548393,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00213-021-05767-1","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T09:04:45Z","timestamp":1611392685000},"page":"917-926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment"],"prefix":"10.1007","volume":"238","author":[{"given":"Jason","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanna M. W.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Lipsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle S.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Nasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kratiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartej","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehala","family":"Subramaniapillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,23]]},"reference":[{"key":"5767_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","volume":"67","author":"M aan het Rot","year":"2010","unstructured":"aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67:139\u2013145. https:\/\/doi.org\/10.1016\/j.biopsych.2009.08.038","journal-title":"Biol Psychiatry"},{"key":"5767_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.biocel.2008.02.011","volume":"41","author":"SJ Assinder","year":"2009","unstructured":"Assinder SJ, Stanton JAL, Prasad PD (2009) Transgelin: an actin-binding protein and tumour suppressor. Int J Biochem Cell Biol 41:482\u2013486. https:\/\/doi.org\/10.1016\/j.biocel.2008.02.011","journal-title":"Int J Biochem Cell Biol"},{"key":"5767_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/2051-5960-1-64","volume":"1","author":"SC Baker","year":"2013","unstructured":"Baker SC, Stahlschmidt J, Oxley J, Hinley J, Eardley I, Marsh F, Gillatt D, Fulford S, Southgate J (2013) Nerve hyperplasia: A unique feature of ketamine cystitis. Acta Neuropathol Commun 1:64. https:\/\/doi.org\/10.1186\/2051-5960-1-64","journal-title":"Acta Neuropathol Commun"},{"key":"5767_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.ajpath.2015.12.014","volume":"186","author":"SC Baker","year":"2016","unstructured":"Baker SC, Shabir S, Georgopoulos NT, Southgate J (2016) Ketamine-induced apoptosis in normal human urothelial cells: a direct, N-methyl-d-aspartate receptor-independent pathway characterized by mitochondrial stress. Am J Pathol 186:1267\u20131277. https:\/\/doi.org\/10.1016\/j.ajpath.2015.12.014","journal-title":"Am J Pathol"},{"key":"5767_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/nau.24341","volume":"39","author":"D Castellani","year":"2020","unstructured":"Castellani D, Pirola GM, Gubbiotti M, Rubilotta E, Gudaru K, Gregori A, Dellabella M (2020) What urologists need to know about ketamine-induced uropathy: a systematic review. Neurourol Urodyn 39:1049\u20131062. https:\/\/doi.org\/10.1002\/nau.24341","journal-title":"Neurourol Urodyn"},{"key":"5767_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1517\/17425250903505108","volume":"6","author":"JT Chen","year":"2010","unstructured":"Chen JT, Chen RM (2010) Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression. Expert Opin Drug Metab Toxicol 6:273\u2013281. https:\/\/doi.org\/10.1517\/17425250903505108","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"5767_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3892\/ijmm.2013.1376","volume":"32","author":"Z Chen","year":"2013","unstructured":"Chen Z, Liu M, Liu X, Huang S, Li L, Song B, Li H, Ren Q, Hu Z, Zhou Y, Qiao L (2013) COX-2 regulates E-cadherin expression through the NF-\u03baB\/Snail signaling pathway in gastric cancer. Int J Mol Med 32:93\u2013100. https:\/\/doi.org\/10.3892\/ijmm.2013.1376","journal-title":"Int J Mol Med"},{"key":"5767_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1747-597X-9-39","volume":"9","author":"WY Chen","year":"2014","unstructured":"Chen WY, Huang MC, Lin SK (2014) Gender differences in subjective discontinuation symptoms associated with ketamine use. Subst Abuse Treat Prev Policy 9:39. https:\/\/doi.org\/10.1186\/1747-597X-9-39","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"5767_CR9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/j.1464-410X.2008.07920.x","volume":"102","author":"PSK Chu","year":"2008","unstructured":"Chu PSK, Ma WK, Wong SCW, Chu RWH, Cheng CH, Wong S, Tse JML, Lau FL, Yiu MK, Man CW (2008) The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 102:1616\u20131622. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.07920.x","journal-title":"BJU Int"},{"key":"5767_CR10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/nau.22367","volume":"32","author":"SM Chuang","year":"2013","unstructured":"Chuang SM, Liu KM, Li YL, Jang MY, Lee HH, Wu WJ, Chang WC, Levin RM, Juan YS (2013) Dual involvements of cyclooxygenase and nitric oxide synthase expressions in ketamine-induced ulcerative cystitis in rat bladder. Neurourol Urodyn 32:1137\u20131143. https:\/\/doi.org\/10.1002\/nau.22367","journal-title":"Neurourol Urodyn"},{"key":"5767_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/nau.22438","volume":"33","author":"CD Cruz","year":"2014","unstructured":"Cruz CD (2014) Neurotrophins in bladder function: what do we know and where do we go from here? Neurourol Urodyn 33:39\u201345. https:\/\/doi.org\/10.1002\/nau.22438","journal-title":"Neurourol Urodyn"},{"key":"5767_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. JAMA Psychiatry 75:139\u2013148. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.3739","journal-title":"JAMA Psychiatry"},{"key":"5767_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Manji H, Drevets WC, Singh JB (2019) Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 76:893\u2013903. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1189","journal-title":"JAMA Psychiatry"},{"key":"5767_CR14","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.3892\/etm.2017.4913","volume":"14","author":"Q Duan","year":"2017","unstructured":"Duan Q, Wu T, Yi X, Liu L, Yan J, Lu Z (2017) Changes to the bladder epithelial barrier are associated with ketamine-induced cystitis. Exp Ther Med 14:2757\u20132762. https:\/\/doi.org\/10.3892\/etm.2017.4913","journal-title":"Exp Ther Med"},{"key":"5767_CR15","doi-asserted-by":"publisher","first-page":"542168","DOI":"10.1155\/2013\/542168","volume":"2013","author":"FJ Enguita","year":"2013","unstructured":"Enguita FJ, Leit\u00e3o AL (2013) Hydroquinone: environmental pollution, toxicity, and microbial answers. Biomed Res Int 2013:542168\u2013542114. https:\/\/doi.org\/10.1155\/2013\/542168","journal-title":"Biomed Res Int"},{"key":"5767_CR16","doi-asserted-by":"publisher","unstructured":"Feifel D, Dadiomov D, Lee C K (2020) Safety of repeated administration of parenteral ketamine for depression. Pharmaceuticals (Basel) 13. https:\/\/doi.org\/10.3390\/ph13070151","DOI":"10.3390\/ph13070151"},{"key":"5767_CR17","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00213-020-05611-y","volume":"237","author":"H Findeis","year":"2020","unstructured":"Findeis H, Sauer C, Cleare A, Bauer M, Ritter P (2020) Urothelial toxicity of esketamine in the treatment of depression. Psychopharmacology (Berl). 237:3295\u20133302. https:\/\/doi.org\/10.1007\/s00213-020-05611-y","journal-title":"Psychopharmacology (Berl)."},{"key":"5767_CR18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/bja\/53.8.805","volume":"53","author":"IS Grant","year":"1981","unstructured":"Grant IS, Nimmo WS, Clements JA (1981) Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 53:805\u2013810. https:\/\/doi.org\/10.1093\/bja\/53.8.805","journal-title":"Br J Anaesth"},{"key":"5767_CR19","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/iju.12100","volume":"20","author":"D Gu","year":"2013","unstructured":"Gu D, Huang J, Shan Z, Yin Y, Zheng S, Wu P (2013) Effects of long-term ketamine administration on rat bladder protein levels: a proteomic investigation using two-dimensional difference gel electrophoresis system. Int J Urol 20:1024\u20131031. https:\/\/doi.org\/10.1111\/iju.12100","journal-title":"Int J Urol"},{"key":"5767_CR20","doi-asserted-by":"publisher","first-page":"7313","DOI":"10.1007\/s11033-014-3616-5","volume":"41","author":"D Gu","year":"2014","unstructured":"Gu D, Huang J, Yin Y, Shan Z, Zheng S, Wu P (2014) Long-term ketamine abuse induces cystitis in rats by impairing the bladder epithelial barrier. Mol Biol Rep 41:7313\u20137322. https:\/\/doi.org\/10.1007\/s11033-014-3616-5","journal-title":"Mol Biol Rep"},{"key":"5767_CR21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/s1065-6995(03)00175-6","volume":"27","author":"K Jezernik","year":"2003","unstructured":"Jezernik K, Romih R, Mannherz HG, Koprivec D (2003) Immunohistochemical detection of apoptosis, proliferation and inducible nitric oxide synthase in rat urothelium damaged by cyclophosphamide treatment. Cell Biol Int 27:863\u2013869. https:\/\/doi.org\/10.1016\/s1065-6995(03)00175-6","journal-title":"Cell Biol Int"},{"key":"5767_CR22","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.juro.2014.05.084","volume":"192","author":"JF Jhang","year":"2014","unstructured":"Jhang JF, Hsu YH, Jiang YH, Kuo HC (2014) Elevated serum IgE may be associated with development of ketamine cystitis. J Urol 192:1249\u20131256. https:\/\/doi.org\/10.1016\/j.juro.2014.05.084","journal-title":"J Urol"},{"key":"5767_CR23","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/iju.12841","volume":"22","author":"JF Jhang","year":"2015","unstructured":"Jhang JF, Hsu YH, Kuo HC (2015) Possible pathophysiology of ketamine-related cystitis and associated treatment strategies. Int J Urol 22:816\u2013825. https:\/\/doi.org\/10.1111\/iju.12841","journal-title":"Int J Urol"},{"key":"5767_CR24","first-page":"E581","volume":"19","author":"JF Jhang","year":"2016","unstructured":"Jhang JF, Hsu YH, Jiang YH, Kuo HC (2016) The role of immunoglobulin E in the pathogenesis of ketamine related cystitis and ulcerative interstitial cystitis: an immunohistochemical study. Pain Physician 19:E581\u2013E587","journal-title":"Pain Physician"},{"key":"5767_CR25","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/nau.23514","volume":"37","author":"JF Jhang","year":"2018","unstructured":"Jhang JF, Hsu YH, Jiang YH, Lee CL, Kuo HC (2018) Histopathological characteristics of ketamine-associated uropathy and their clinical association. Neurourol Urodyn 37:1764\u20131772. https:\/\/doi.org\/10.1002\/nau.23514","journal-title":"Neurourol Urodyn"},{"key":"5767_CR26","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1002\/nau.24139","volume":"38","author":"JF Jhang","year":"2019","unstructured":"Jhang JF, Wang HJ, Hsu YH, Birder LA, Kuo HC (2019) Upregulation of neurotrophins and transforming growth factor-\u03b2 expression in the bladder may lead to nerve hyperplasia and fibrosis in patients with severe ketamine-associated cystitis. Neurourol Urodyn 38:2303\u20132310. https:\/\/doi.org\/10.1002\/nau.24139","journal-title":"Neurourol Urodyn"},{"key":"5767_CR27","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1016\/j.ajpath.2015.04.020","volume":"185","author":"YS Juan","year":"2015","unstructured":"Juan YS, Lee YL, Long CY, Wong JH, Jang MY, Lu JH, Wu WJ, Huang YS, Chang WC, Chuang SM (2015) Translocation of NF-\u03baB and expression of cyclooxygenase-2 are enhanced by ketamine-induced ulcerative cystitis in rat bladder. Am J Pathol 185:2269\u20132285. https:\/\/doi.org\/10.1016\/j.ajpath.2015.04.020","journal-title":"Am J Pathol"},{"key":"5767_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.drugalcdep.2014.06.043","volume":"142","author":"X Ke","year":"2014","unstructured":"Ke X, Ding Y, Xu K, He H, Zhang M, Wang D, Deng X, Zhang X, Zhou C, Liu Y, Ning Y, Fan N (2014) Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers. Drug Alcohol Depend 142:290\u2013294. https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.06.043","journal-title":"Drug Alcohol Depend"},{"key":"5767_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1903305","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim J, Farchione T, Potter A, Chen Q, Temple R (2019) Esketamine for treatment-resistant depression\u2014first FDA-approved antidepressant in a new class. N Engl J Med 381:1\u20134. https:\/\/doi.org\/10.1056\/NEJMp1903305","journal-title":"N Engl J Med"},{"key":"5767_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","volume":"72","author":"J Kryst","year":"2020","unstructured":"Kryst J, Kawalec P, Mitoraj AM, Pilc A, Laso\u0144 W, Brzostek T (2020) Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep 72:543\u2013562. https:\/\/doi.org\/10.1007\/s43440-020-00097-z","journal-title":"Pharmacol Rep"},{"key":"5767_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000338098","volume":"89","author":"Y Lai","year":"2012","unstructured":"Lai Y, Wu S, Ni L, Chen Z, Li X, Yang S, Gui Y, Guan Z, Cai Z, Ye J (2012) Ketamine-associated urinary tract dysfunction: an underrecognized clinical entity. Urol Int 89:93\u201396. https:\/\/doi.org\/10.1159\/000338098","journal-title":"Urol Int"},{"key":"5767_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15:178\u2013196. https:\/\/doi.org\/10.1038\/nrm3758","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5767_CR33","first-page":"15","volume":"4","author":"P Lee","year":"2009","unstructured":"Lee P, Ong T, Chua C, Lei C, Teh G (2009) Street ketamine-associated bladder dysfunction: an emerging health problem. Malays Fam Physician 4:15\u201318","journal-title":"Malays Fam Physician"},{"key":"5767_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.juro.2011.03.037","volume":"186","author":"WC Lee","year":"2011","unstructured":"Lee WC, Chuang YC, Chiang PH, Chien CT, Yu HJ, Wu CC (2011) Pathophysiological studies of overactive bladder and bladder motor dysfunction in a rat model of metabolic syndrome. J Urol 186:318\u2013325. https:\/\/doi.org\/10.1016\/j.juro.2011.03.037","journal-title":"J Urol"},{"key":"5767_CR35","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/bju.12256","volume":"112","author":"CL Lee","year":"2013","unstructured":"Lee CL, Jiang YH, Kuo HC (2013) Increased apoptosis and suburothelial inflammation in patients with ketamine-related cystitis: a comparison with non-ulcerative interstitial cystitis and controls. BJU Int 112:1156\u20131162. https:\/\/doi.org\/10.1111\/bju.12256","journal-title":"BJU Int"},{"key":"5767_CR36","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1038\/onc.2011.161","volume":"30","author":"WKC Leung","year":"2011","unstructured":"Leung WKC, Ching AKK, Chan AWH, Poon TCW, Mian H, Wong AST, To KF, Wong N (2011) A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene 30:4464\u20134475. https:\/\/doi.org\/10.1038\/onc.2011.161","journal-title":"Oncogene"},{"key":"5767_CR37","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.3892\/mmr.2014.3110","volume":"11","author":"HC Lin","year":"2015","unstructured":"Lin HC, Lee HS, Chiueh TS, Lin YC, Lin HA, Lin YC, Cha TL, Meng E (2015) Histopathological assessment of inflammation and expression of inflammatory markers in patients with ketamine-induced cystitis. Mol Med Rep 11:2421\u20132428. https:\/\/doi.org\/10.3892\/mmr.2014.3110","journal-title":"Mol Med Rep"},{"key":"5767_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160578","volume":"11","author":"CC Lin","year":"2016","unstructured":"Lin CC, Lin ATL, Yang AH, Chen KK (2016) Microvascular injury in ketamine-induced bladder dysfunction. PloS One 11:e0160578. https:\/\/doi.org\/10.1371\/journal.pone.0160578","journal-title":"PloS One"},{"key":"5767_CR39","first-page":"121","volume":"35","author":"A Lopez-Beltran","year":"2013","unstructured":"Lopez-Beltran A, Montironi R, Vidal A, Scarpelli M, Cheng L (2013) Urothelial dysplasia of the bladder: diagnostic features and clinical significance. Anal Quant Cytopathol Histpathol 35:121\u2013129","journal-title":"Anal Quant Cytopathol Histpathol"},{"key":"5767_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/bja\/77.2.203","volume":"77","author":"JM Malinovsky","year":"1996","unstructured":"Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M (1996) Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth 77:203\u2013207. https:\/\/doi.org\/10.1093\/bja\/77.2.203","journal-title":"Br J Anaesth"},{"key":"5767_CR41","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jad.2020.05.088","volume":"274","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Rodrigues NB, Lee Y, Lipsitz O, Subramaniapillai M, Gill H, Nasri F, Majeed A, Lui LMW, Senyk O, Phan L, Carvalho IP, Siegel A, Mansur RB, Brietzke E, Kratiuk K, Arekapudi AK, Abrishami A, Chau EH et al (2020) The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. J Affect Disord 274:903\u2013910. https:\/\/doi.org\/10.1016\/j.jad.2020.05.088","journal-title":"J Affect Disord"},{"key":"5767_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","volume":"107","author":"CJA Morgan","year":"2012","unstructured":"Morgan CJA, Curran HV, Independent Scientific Committee on Drugs (2012) Ketamine use: a review. Addiction 107:27\u201338. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03576.x","journal-title":"Addiction"},{"key":"5767_CR43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.cll.2016.07.008","volume":"36","author":"FA Myers","year":"2016","unstructured":"Myers FA, Bluth MH, Cheung WW (2016) Ketamine: a cause of urinary tract dysfunction. Clin Lab Med 36:721\u2013744. https:\/\/doi.org\/10.1016\/j.cll.2016.07.008","journal-title":"Clin Lab Med"},{"key":"5767_CR44","doi-asserted-by":"publisher","first-page":"110060","DOI":"10.1016\/j.pnpbp.2020.110060","volume":"104","author":"KS Na","year":"2021","unstructured":"Na KS, Kim YK (2021) Increased use of ketamine for the treatment of depression: benefits and concerns. Prog Neuropsychopharmacol Biol Psychiatry 104:110060. https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110060","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"5767_CR45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/j.1365-2559.2009.03437.x","volume":"55","author":"JD Oxley","year":"2009","unstructured":"Oxley JD, Cottrell AM, Adams S, Gillatt D (2009) Ketamine cystitis as a mimic of carcinoma in situ. Histopathology 55:705\u2013708. https:\/\/doi.org\/10.1111\/j.1365-2559.2009.03437.x","journal-title":"Histopathology"},{"key":"5767_CR46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/08998280.2014.11929117","volume":"27","author":"JM Pappachan","year":"2014","unstructured":"Pappachan JM, Raj B, Thomas S, Hanna FW (2014) Multiorgan dysfunction related to chronic ketamine abuse. Proc (Bayl Univ Med Cent) 27:223\u2013225. https:\/\/doi.org\/10.1080\/08998280.2014.11929117","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"5767_CR47","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jchromb.2008.09.036","volume":"876","author":"MC Parkin","year":"2008","unstructured":"Parkin MC, Turfus SC, Smith NW, Halket JM, Braithwaite RA, Elliott SP, Osselton MD, Cowan DA, Kicman AT (2008) Detection of ketamine and its metabolites in urine by ultra high pressure liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 876:137\u2013142. https:\/\/doi.org\/10.1016\/j.jchromb.2008.09.036","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"5767_CR48","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/bju.12291","volume":"112","author":"H Payne","year":"2013","unstructured":"Payne H, Adamson A, Bahl A, Borwell J, Dodds D, Heath C, Huddart R, McMenemin R, Patel P, Peters JL, Thompson A (2013) Chemical- and radiation-induced haemorrhagic cystitis: Current treatments and challenges. BJU Int 112:885\u2013897. https:\/\/doi.org\/10.1111\/bju.12291","journal-title":"BJU Int"},{"key":"5767_CR49","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","volume":"55","author":"MA Peltoniemi","year":"2016","unstructured":"Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI (2016) Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet 55:1059\u20131077. https:\/\/doi.org\/10.1007\/s40262-016-0383-6","journal-title":"Clin Pharmacokinet"},{"key":"5767_CR50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1054\/bjoc.2000.1233","volume":"83","author":"Z Popov","year":"2000","unstructured":"Popov Z, Gil-Diez de Medina S, Lefrere-Belda MA, Hoznek A, Bastuji-Garin S, Abbou CC, Thiery JP, Radvanyi F, Chopin DK (2000) Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br J Cancer 83:209\u2013214. https:\/\/doi.org\/10.1054\/bjoc.2000.1233","journal-title":"Br J Cancer"},{"key":"5767_CR51","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/14740338.2020.1776699","volume":"19","author":"NB Rodrigues","year":"2020","unstructured":"Rodrigues NB, McIntyre RS, Lipsitz O, Lee Y, Cha DS, Nasri F, Gill H, Lui LMW, Subramaniapillai M, Kratiuk K, Lin K, Ho R, Mansur RB, Rosenblat JD (2020) Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. Expert Opin Drug Saf 19:1031\u20131040. https:\/\/doi.org\/10.1080\/14740338.2020.1776699","journal-title":"Expert Opin Drug Saf"},{"key":"5767_CR52","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905\u20131917. https:\/\/doi.org\/10.1176\/ajp.2006.163.11.1905","journal-title":"Am J Psychiatry"},{"key":"5767_CR53","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","volume":"74","author":"G Sanacora","year":"2017","unstructured":"Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB, American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 74:399\u2013405. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.0080","journal-title":"JAMA Psychiatry"},{"key":"5767_CR54","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.urology.2007.01.038","volume":"69","author":"R Shahani","year":"2007","unstructured":"Shahani R, Streutker C, Dickson B, Stewart RJ (2007) Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69:810\u2013812. https:\/\/doi.org\/10.1016\/j.urology.2007.01.038","journal-title":"Urology"},{"key":"5767_CR55","doi-asserted-by":"publisher","unstructured":"Shie JH, Liu HT, Kuo HC (2012) Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis\/painful bladder syndrome. Urology 79:484.e7-13. https:\/\/doi.org\/10.1016\/j.urology.2011.09.049","DOI":"10.1016\/j.urology.2011.09.049"},{"key":"5767_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","volume":"5","author":"B Short","year":"2018","unstructured":"Short B, Fong J, Galvez V, Shelker W, Loo CK (2018) Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 5:65\u201378. https:\/\/doi.org\/10.1016\/S2215-0366(17)30272-9","journal-title":"Lancet Psychiatry"},{"key":"5767_CR57","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","volume":"173","author":"JB Singh","year":"2016","unstructured":"Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L (2016) A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 173:816\u2013826. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16010037","journal-title":"Am J Psychiatry"},{"key":"5767_CR58","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3109\/01480545.2015.1079916","volume":"39","author":"M Song","year":"2016","unstructured":"Song M, Yu HY, Chun JY, Shin DM, Song SH, Choo MS, Song YS (2016) The fibrosis of ketamine, a noncompetitive N-methyl-d-aspartic acid receptor antagonist dose-dependent change in a ketamine-induced cystitis rat model. Drug Chem Toxicol 39:206\u2013212. https:\/\/doi.org\/10.3109\/01480545.2015.1079916","journal-title":"Drug Chem Toxicol"},{"key":"5767_CR59","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/jemt.21014","volume":"74","author":"S Tan","year":"2011","unstructured":"Tan S, Chan WM, Wai MSM, Hui LKK, Hui VWK, James AE, Yeung LY, Yew DT (2011) Ketamine effects on the urogenital system\u2014changes in the urinary bladder and sperm motility. Microsc Res Tech 74:1192\u20131198. https:\/\/doi.org\/10.1002\/jemt.21014","journal-title":"Microsc Res Tech"},{"key":"5767_CR60","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1742-1241.2004.00421.x","volume":"59","author":"PS Teegavarapu","year":"2005","unstructured":"Teegavarapu PS, Sahai A, Chandra A, Dasgupta P, Khan MS (2005) Eosinophilic cystitis and its management. Int J Clin Pract 59:356\u2013360. https:\/\/doi.org\/10.1111\/j.1742-1241.2004.00421.x","journal-title":"Int J Clin Pract"},{"key":"5767_CR61","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RYJ, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871\u2013890. https:\/\/doi.org\/10.1016\/j.cell.2009.11.007","journal-title":"Cell"},{"key":"5767_CR62","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2174\/1389557511313020009","volume":"13","author":"MSM Wai","year":"2013","unstructured":"Wai MSM, Luan P, Jiang Y, Chan WM, Tsui TYM, Tang HC, Lam WP, Fan M, Yew DT (2013) Long term ketamine and ketamine plus alcohol toxicity\u2014what can we learn from animal models? Mini Rev Med Chem 13:273\u2013279. https:\/\/doi.org\/10.2174\/1389557511313020009","journal-title":"Mini Rev Med Chem"},{"key":"5767_CR63","doi-asserted-by":"publisher","unstructured":"Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, Grunfeld J, Jeon HJ, Wilkinson ST, Drevets WC, Singh JB (2020) Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry 81. https:\/\/doi.org\/10.4088\/JCP.19m12891","DOI":"10.4088\/JCP.19m12891"},{"key":"5767_CR64","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","volume":"72","author":"ER Walker","year":"2015","unstructured":"Walker ER, McGee RE, Druss BG (2015) Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72:334\u2013341. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.2502","journal-title":"JAMA Psychiatry"},{"key":"5767_CR65","doi-asserted-by":"publisher","first-page":"F961","DOI":"10.1152\/ajprenal.00686.2016","volume":"313","author":"J Wang","year":"2017","unstructured":"Wang J, Chen Y, Gu D, Zhang G, Chen J, Zhao J, Wu P (2017) Ketamine-induced bladder fibrosis involves epithelial-to-mesenchymal transition mediated by transforming growth factor-\u03b21. Am J Physiol Renal Physiol 313:F961\u2013F972. https:\/\/doi.org\/10.1152\/ajprenal.00686.2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"5767_CR66","doi-asserted-by":"publisher","first-page":"341","DOI":"10.12809\/hkmj134013","volume":"19","author":"YB Wei","year":"2013","unstructured":"Wei YB, Yang JR, Yin Z, Guo Q, Liang BL, Zhou KQ (2013) Genitourinary toxicity of ketamine. Hong Kong Med J 19:341\u2013348. https:\/\/doi.org\/10.12809\/hkmj134013","journal-title":"Hong Kong Med J"},{"key":"5767_CR67","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/j.1464-410X.2012.11028.x","volume":"110","author":"AR Winstock","year":"2012","unstructured":"Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM (2012) The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int 110:1762\u20131766. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11028.x","journal-title":"BJU Int"},{"key":"5767_CR68","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"TA Wynn","year":"2012","unstructured":"Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18:1028\u20131040. https:\/\/doi.org\/10.1038\/nm.2807","journal-title":"Nat Med"},{"key":"5767_CR69","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/00129039-200609000-00002","volume":"14","author":"H Yin","year":"2006","unstructured":"Yin H, He Q, Li T, Leong ASY (2006) Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol 14:260\u2013265. https:\/\/doi.org\/10.1097\/00129039-200609000-00002","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"5767_CR70","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.tibs.2019.05.004","volume":"44","author":"LM Yin","year":"2019","unstructured":"Yin LM, Ulloa L, Yang YQ (2019) Transgelin-2: Biochemical and clinical implications in cancer and asthma. Trends Biochem Sci 44:885\u2013896. https:\/\/doi.org\/10.1016\/j.tibs.2019.05.004","journal-title":"Trends Biochem Sci"},{"key":"5767_CR71","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA, Gould TD (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70:621\u2013660. https:\/\/doi.org\/10.1124\/pr.117.015198","journal-title":"Pharmacol Rev"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05767-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-021-05767-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05767-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T09:22:59Z","timestamp":1615972979000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-021-05767-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,23]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["5767"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-05767-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,23]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Roger McIntyre has received research grant support from CIHR\/GACD\/Chinese National Natural Research Foundation; speaker\/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, Minerva, Intra-Cellular, Abbvie, and Eisai. Dr. Roger McIntyre is a shareholder and CEO of Champignon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}